Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 926 - 950 of 14557 in total
Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Approved
Investigational
A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Approved
Matched Description: … A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and
Matched Categories: … Metabolic Side Effects of Drugs and Substances …
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Approved
Matched Description: … peripheral origin, and as an adjuvant in the therapy of epilepsy. ... Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 ... effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and
Matched Categories: … Calcium-Regulating Hormones and Agents …
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Description: … [L43277] Niraparib is selective towards PARP-1 and PARP-2. ... [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health …
Matched Categories: … niraparib and abiraterone ... Antineoplastic and Immunomodulating Agents …
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity...
Approved
Investigational
Matched Description: … Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into ... It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel ... cardiac and arterial smooth muscle cells. …
Matched Categories: … Calcium-Regulating Hormones and Agents …
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Flutemetamol (18F) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18. It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Approved
Investigational
Matched Categories: … Indicators and Reagents …
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the...
Approved
Investigational
Matched Description: … Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors ... [A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as ... promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and
Matched Categories: … Serotonin antagonist and reuptake inhibitors (SARIs) …
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention...
Approved
Matched Description: … considered the most effective and first-line treatment for ADHD in adults and children as recommended ... addictive properties, and even amplifies the potency and reinforcing effects of other drugs of abuse ... amphetamines, have a high potential for abuse and dependence. …
Matched Categories: … Psychostimulants, Agents Used for ADHD and Nootropics …
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline...
Approved
Investigational
Matched Description: … of serotonin reuptake and has little effect on other neurotransmitters. ... [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. ... uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation...
Approved
Investigational
Matched Description: … [clotrimazole], due to its broad spectrum and good absorption. ... Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal ... Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations. …
Matched Categories: … Sex Hormones and Insulins ... Imidazole and Triazole Derivatives ... Gynecological Antiinfectives and Antiseptics ... Metabolic Side Effects of Drugs and Substances …
Secretin porcine stimulates pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine dysfunction and the diagnosis of gastrinoma.
Approved
Matched Description: … dysfunction and the diagnosis of gastrinoma. ... Secretin porcine stimulates pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine …
Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis....
Approved
Investigational
Matched Description: … It is prepared from the Connaught strain of Bacillus Calmette and Guérin. ... recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). ... prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or …
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Description: … is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that...
Approved
Investigational
Matched Description: … Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain ... Imiquimod does not cure warts, and new warts may appear during treatment. ... Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. …
Matched Categories: … Skin and Mucous Membrane Agents …
An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of...
Approved
Illicit
Matched Description: … the eye, ear, nose, and throat. ... It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in ... It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse …
Matched Categories: … Analgesics and Anesthetics …
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive...
Approved
Investigational
Matched Description: … as amitriptyline and clomipramine. ... TCAs are potent inhibitors of serotonin and norepinephrine reuptake. ... reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. …
Matched Categories: … Tricyclics and Other Norepinephrine-reuptake Inhibitors …
Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown...
Approved
Investigational
Matched Description: … suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and
Matched Categories: … moxonidine and diuretics …
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or...
Approved
Investigational
Matched Description: … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Description: … [A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation. …
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval...
Approved
Investigational
Matched Description: … [L2933] It is administered orally and is odorless, tasteless, and stable at room temperature. ... Approval of the medication is supported by data from three double-blind, placebo-controlled trials and ... two open-label trials which showed that the onset of action was approximately 1.0 hour and the median …
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related ... of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and ... [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and
Approved
Experimental
Matched Categories: … Diet, Food, and Nutrition …
A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being...
Approved
Illicit
Matched Description: … benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and ... , however, like most benzodiazepines, clonazepam use has also been associated with recreational use and ... [FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Description: … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 926 - 950 of 14557 in total